MAY 0 6 2006 MAY

#IfW

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

A

Loriann Kazmercyk

Type or print name

Jan Signature

May 3, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: McPhee et al.

Art Unit: 1654

Application No.: 10/825,693

Examiner: Thomas S. Heard

Filed: April 16, 2004

Docket No. CT-2770-NP

For: MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(a)

Sir:

This is a petition to add

Kenneth M. Boy

as an inventor of the above-identified patent application. The correct inventors should be Stanley D'Andrea, Zhizhen Barbara Zheng, David J. Carini, Barry L. Johnson, Jeffrey Allen Campbell, Kenneth M. Boy, Fiona Mcphee, Andrew Charles Good, and Paul Michael Scola.

In support of this petition, the following documents are included herewith:

- 1) Statement of Inventor to be Added and Written Consent of Assignee;
- 2) A newly executed Declaration including all of the inventors;

3) A copy of Assignment Recordation Document dated June 8, 2005; and

4) A copy of the Assignment document submitted on March 9, 2005.

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$130 for payment of the fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.17(i) which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (203) 677-7669

Date: May 3, 2006

Pamela A. Mingo, Ph.D. Agent for Applicants

Reg. No. 48,256



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Loriann Kazmercyk

Type or print name

hatter May

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: McPhee et al.

Art Unit: 1654

Application No.: 10/825,693

Examiner: Thomas S. Heard

Filed: April 16, 2004

Docket No.: CT-2770-NP

For: MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT OF INVENTORS FOR CORRECTION OF INVENTORSHIP UNDER 37 CFR 1.48(a)(2)

Sir:

- 1. Now comes Kenneth M. Boy who deposes and says that his name was erroneously excluded as a joint inventor of the above-identified application and that he contributed to inventive aspects of the present invention claimed therein. This error occurred without deceptive intent.
- 2. It is requested that Kenneth M. Boy be added as an inventor of the above-identified application. Thus, the inventorship of the above-identified application should be changed from Fiona Mcphee, Jeffrey Allen Campbell, Wenying Li, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, and Paul Michael Scola to Stanley D'Andrea, Zhizhen Barbara Zheng, David J. Carini, Barry L. Johnson, Jeffrey Allen Campbell, Kenneth M. Boy, Fiona Mcphee, Andrew Charles

Good, and Paul Michael Scola. Wenying Li was previously deleted as an inventor due to a change in the claimed invention.

- 3. The Commissioner is authorized to charge the fee of \$130.00, set forth under 37 CFR 1.17(i), and any additional fees that may be required to Account No. 19-3880.
- 4. The undersigned Petitioner declares further that all statements made herein of his own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.
- 5. Further, the deponent saith not.

Date: 3/23/2006

Kenneth M. Boy

CONSENT OF ASSIGNEE UNDER 37 CFR 1.48(a)

6. Petitioners, Bristol-Myers Squibb Company, are the owners of the entire right, title and interest in and to the invention claimed and disclosed in the above-identified application by virtue of assignment. Petitioners hereby consent to a change in inventorship in the above-identified application from Fiona Mcphee, Jeffrey Allen Campbell, Wenying Li, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, and Paul Michael Scola to Stanley D'Andrea, Zhizhen Barbara Zheng, David J. Carini, Barry L. Johnson, Jeffrey Allen Campbell, Kenneth M. Boy, Fiona Mcphee, Andrew Charles Good, and Paul Michael Scola. Wenying Li was previously deleted as an inventor due to a change in the claimed invention.

CERTIFICATION UNDER 37 CFR 3.73(b)

I, the undersigned, certify that I am an individual empowered to act on behalf of the Petitioner, Bristol-Myers Squibb Company, a corporation, the assignee of the entire right, title and interest of the above-identified application by virtue of an Assignment from the inventors of the application. I further certify that the Assignment has been recorded in the U.S. Patent and Trademark Office at Reel No. 015864, Frame 0775, on March 9, 2005, that I have reviewed that Assignment recorded at the reel and frame, and that to the best of my knowledge and belief, title is in the above-noted assignee.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Date: May 3, 2006

Pamera A. Mingo, Ph.D. Agent for Applicants

Reg. No. 48,256

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (203)-677-7669



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Loriann Kazmercyk

Type or print name



May 3, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: McPhee et al.

Art Unit: 1654

Application No.: 10/825,693

Examiner: Thomas S. Heard

Filed: April 16, 2004

Docket No.: CT-2770-NP

For: MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE DECLARATION

Sir:

Applicants hereby submit a Substitute Declaration for the above-captioned matter.

The Commissioner is hereby authorized to charge the \$130.00 fee under 37 CFR 1.17(i) and any additional fees that may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is enclosed.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (203)-677-7669

Date: My 3, 2006

Pamela A. Mingo, Ph.D.

Agent for Applicants

Reg. No. 48,256